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Abstract 
Purpose: To investigate the microbiological quality of blister-packed tablets manufactured and 
marketed in Jordan in order to assess Good Manufacturing Practice by pharmaceutical industries in the 
country. 
Methods: A total of 66 items of 22 registered blister-packed tablet brands were purchased from 
community pharmacies in Amman. All the items were investigated for total bacterial count and the 
presence of specified microorganisms using compendial procedures.  
Results: Out of 66 items purchased, forty eight (72.7 %) products were free from microbial 
contamination, while 11 (16.7 %) harbored bacteria in counts < 102 cfu/g. The remaining 7 (10.6 %) 
items contained counts between 102 and < 103 cfu/g. The most commonly encountered contaminant 
was Bacillus species but specified objectionable bacteria such as Escherichia coli and Staphylococcus 
aereus were not detected. Aspergillus and Penicillium species were isolated in low numbers from few 
products. Six of the products with the highest stratified bacterial count were manufactured by one 
company and were also found to be contaminated with Aeromonas species.  
Conclusion: This study demonstrates that blister-packed tablets produced by Jordanian 
pharmaceutical companies are within acceptable microbiological quality but the detection of microbial 
load in some brands close to the maximum allowable limit suggests the need for better adherence to 
GMP in the country.  
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Oral dosage forms including tablets are not 
required to be sterile, but certain quality control 
measures are essential to keep the microbial 
content of these preparations safe and 
acceptable [1]. The extent of microbial 
contamination in tablets is usually influenced by 
the microbiological quality of the starting raw 
materials, packaging materials, personnel that 
come in contact with the product during the 
manufacturing process and the production 
environment as well as equipment. Failure to 
observe Good Manufacturing Practice (GMP) at 
any stage of production may consequently affect 
the microbiological quality of the product. 
Contaminants entrapped into the product via the 
above mentioned routes may not survive for a 
long period of time due to the lethal effect 
exerted by the various methods used in tablet 
production [2].  
 
A recent survey carried out in Egypt [3] 
demonstrated that microbial contamination of 
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tablets was the lowest of all non-sterile 
pharmaceutical preparations. However, alarming 
figures of tablets microbial load appeared in 
other publications [4-6]. High contamination 
levels were detected in tablets distributed by 
industries in containers and then dispensed to 
patients by counting.  
 
In Jordan, marketed tablets are mostly packed in 
blisters. Hence, microbial contamination of these 
products is unlikely to occur after the packaging 
step in the manufacturing facility. High levels of 
microbial contamination in blister-packed tablets 
may indicate irregularities in the implementation 
of GMP standards by manufacturers. The 
objectives of this study were, first to investigate 
the microbiological quality of tablets 
manufactured and marketed in Jordan, and then 
to apply the results obtained to extrapolate the 
degree of pharmaceutical companies’ adherence 






Twenty two different brands of tablet dosage 
forms that contained 8 pharmaceutical active 
ingredients were randomly purchased from 
community pharmacies with preference for 
formulations with high public demand such as 
metformin, glibenclamide, acetylsalicylic acid and 
diclofenac salts. All purchased items were 
manufactured by companies registered in Jordan 
and their drugs approved by the Jordan Food 
and Drug Administration (JFDA). For each brand, 
3 Paks with different batch numbers were 
obtained. Each purchased item was inspected for 
the information disclosed on the container label, 
including amount of active ingredients, 
manufacture date, and expiry date as well as 
batch number.  
 
Isolation of specified organisms 
 
The blister of each brand was wiped with 70 % 
alcohol, and with the aid of a sterile scalpel, 5 
tablets were taken and placed in a conical flask 
containing 50 ml Tryptic Soya Bean Digest 
(TSBD) broth. The flasks were incubated at 35 
ºC in a shaking water bath for 48 hours before 
1.0 ml aliquots of the flask content were 
processed for the isolation of E. coli, 
Pseudomonas aeruginosa, Staphylococcus 
aureus and Salmonella species as described in 
the United States Pharmacopoeia [1]. 
 
Microbial count  
 
Tablets were taken from the blister pack of each 
purchased item separately as described above, 
crushed in a mortar under aseptic conditions 
before 1 g was added to 9 ml sterile phosphate 
buffer pH 7. The content of each tube was 
shaken vigorously for 2 min using a vortex mixer 
then allowed to stand for 30 minutes. One ml 
aliquot of each tablet supernatant was 10-fold 
serially diluted using similar buffer and kept in a 
standing position for additional 30 minutes. 
Aliquots of 1.0 ml of each dilution were 
separately transferred into Petri dishes and the 
traditional pour plate technique was performed 
using TSBD agar. After 48 hours of incubation at 
35 ºC, developed colonies were counted and 5 of 
the grown colonies with apparently different 
colonial morphology were purified for further 
identification. Isolation and enumeration of yeast 
as well as molds was carried out by spread plate 
technique on Sabouraud’s Dextrose agar 
supplemented with chloramphenicol as a 
bacterial inhibitor. Plates in this case were 
incubated at 27 ºC for 2 weeks but because 
yeasts grow faster than molds, counts for the 
former organisms were performed during the first 
3 days of incubation. The phosphate buffer used 
for microbial count and media employed were 
supplemented with 0.5 % polysorbate 80 as well 
as 0.5 % lecithin as neutralizing agents for 
preservatives, in case the tablets under study 
had been preserved. All media used in this 
investigation were the products of Difco, USA 
 
Identification of isolates  
 
Purified bacterial colonies recovered from 
contaminated samples were identified according 
to the diagnostic tables given by Barrow & 
Feltham [7]. Tests performed for this purpose 
include Gram reaction, shape, carbohydrate 
utilization, catalase production, oxidase test, 
Indole production, spore formation, methyl red, 
Voges Proskauer, nitrate reduction, starch 
hydrolysis, tryptophan hydrolysis, hydrogen 




Sterile phosphate buffer solution was 
supplemented with 0.5 % methyl and 1 % propyl 
parabens. After heating to dissolve, the solution 
was brought to room temperature and then 
challenged with P. aeruginosa ATCC 9027 to 
give a count of 103 cfu/ml. Inoculums' 
standardization was performed using McFarland 
solution and spectrophotometry. One ml of the 
challenged sample was diluted with 9 ml 
phosphate buffer amended with 0.5 % 
polysorbate 80 as well as 0.5 % lecithin. After 
half an hour, a further 10-fold serial dilution using 
similar buffer was made. All dilutions were kept 
at room temperature for additional 30 min to 
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allow preservative neutralization to occur. 
Recovery of at least 50 % of the inoculated 
bacteria on SBCD agar indicated the 
effectiveness of the neutralization process. 
 
Statistical analysis  
 
In order to determine batch to batch variation in 
the numeric data obtained for the 3 packs 
purchased for each brand, statistical analysis to 
establish the deviation from the mean count was 
carried out using t- test with the aid of Sigma Plot 
software. Differences were considered as 




Visual inspection of all items purchased indicated 
that all were neat and un-tampered. Information 
disclosed on the containers included 
manufacturing date, expiry date, batch number 
and concentration of active ingredient in addition 
to cautions that the product was a drug. All 
tablets tested were smooth, without any unusual 
discoloration or indications of surface microbial 
contamination. 
 
The results presented in Table 1 demonstrate 
that out of 66 items investigated, 48 (72.7 %) 
were free from microbial contaminants whereas 
the remaining 18 items (27.3 %), harbored 
bacteria in levels below 103 cfu/g. It is evident 
from the same table that only 10.6 % of the items 
contained bacterial count between 102 and 103 
cfu/g. Three units with different batch numbers 
were analyzed for each brand and as table 1 
shows; the highest contamination level appeared 
predominantly in the triplicate items obtained for 
one brand of metformin and another of 
acetylsalicylic acid. Both brands were 
manufactured by the same company. 
 
Table 2 shows the types of microorganisms 
isolated from each product category. It is clear 
that Bacillus spp was the most commonly 
encountered Gram positive bacteria followed by 
Staphylococcus spp, while Aeromonas spp were 
the only Gram negative bacteria recovered. 
Filamentous fungi were present among the 
contaminants and were represented by 
Aspergillus as well as Penicillium spp but 
Candida spp were not detected. Both fungal 
species were recovered in very low numbers 
which were difficult to enumerate in a 
reproducible manner. It is important to mention 
that fungi were recovered from products 
regardless of the bacterial count detected. Table 
3 provides information regarding the frequency of 
detection for different microorganisms in relation 
to the number of items in which they occurred. 
 
Statistical analysis of the bacterial counts 
obtained indicated that batch to batch variation in 
the microbiological quality was detected for the 
products of two companies. This was deduced  
 
         Table 1: Extent of microbial count of blister packs 
 
Brand/Active ingredient No of units studied per brand Contaminated units (%) 
Level of bacterial  
Contamination/g (%) 
<102 102- < 103 
Metformin 4x3 4 1 3 
Glibenclamide 2x3 2 2 0 
Acetylsalicylic acid 4x3 6 3 3 
Diclofenac salt 3x3 2 2 0 
Lovastatin 2x3 0 0 0 
Chlorpheniramine 3x3 2 2 0 
Ibuprofen 2x3 0 0 0 
Vitamin preparations 2x3 2 1 1 
Total no. 66 18 (27.3) 11 (16.7) 7 (10.6) 
 
      Table 2: Types of microbial contaminants isolated from each brand type 
 
Brand/Active ingredient No. of units studied in each brand Microorganisms isolated 
Metformin 12 Bacillus spp, Molds*, Aeromonas spp 
Glibenclamide 6 Staphylococcus spp, Molds* 
Acetylsalicylic acid 12 Bacillus spp, Molds*, Aeromonas spp 
Diclofenac salt 9 Bacillus spp,  
Lovastatin 6 None 
Chlorpheniramine 9 Staphylococcus spp, Bacillus spp,  
Ibuprofen 6 None 
Multivitamins 6 Molds*, Staphylococcus spp  
       *Aspergillus and/or Penicillium   
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from the variation noted on the bacterial count of 
tablets derived from 3 containers with different 
batch numbers. The deviation of counts from the 
mean was statistically significant at a probability 
level of <0.05. Preservative neutralization test 
indicated the effectiveness of the neutralizers 
used as it was always possible to isolate at least 
50 % of the challenge bacterium used in the test 
 
Table 3: Frequency of contaminants isolated from the 
tablet brands studied. 
 
Type of isolate Frequency of isolation in 
studied units 
Bacillus spp 12 
Aspergillus spp  8 
Penicillium spp 7 
Aeromonas spp 6 
Staphylococcus spp 4 
 
Enrichment culture techniques employed for the 
qualitative recovery of Salmonella, E. coli, 
Staphylococcus aureus and P. aeruginosa 
demonstrated the absence of these organisms 
from all items studied. These results corroborate 




This study is the first to focus on the 
microbiological quality of blister pack tablets 
manufactured and marketed in Jordan. Products 
were chosen according to high public demand by 
the local community; they include anti-diabetic 
drugs, analgesics and vitamin preparations. The 
harmonized pharmacopoeial standards stipulate 
that oral solid dosage forms are required to be 
free from E. coli as a specified organism and 
should not contain a total bacterial count in 
excess of 103 CFU/g [1]. 
 
Findings reported in this communication have 
shown that 72.7 % of the items tested were free 
from microbial contamination whereas 10.6 % 
harbored bacteria in counts between 102 and < 
103 cfu/g. E. coli was not recovered from any of 
the products while, Aspergillus and Penicillium 
spp were present in small numbers in 8 and 7 
items, respectively. Candida spp in addition to 
other pathogenic bacteria such as Salmonella 
spp were not detected. Therefore, according to 
the United States Pharmacopoeia [1], all 
products tested were in compliance with 
specifications in relation to microbial counts and 
absence of specified microorganisms. 
 
Microbial counts obtained in this work were 
different than those reported by Obi and 
Nwannunu [6] who investigated tablets 
dispensed to patients by counting and found that 
all brands they studied harbored microbial count 
in excess of 105 cfu/g. On the other hand, our 
results are close to the findings released from 
Egypt by Gad et al [3]. These authors found that 
out of 80 tablet dosage forms, 10 % were 
contaminated with bacteria in counts ranging 
between 102 and 103 cfu/g, while none 
contained bacteria in excess of 103 cfu/g, in 
amazing agreement with the 10.6 % obtained in 
this work.       
 
Staphylococcus aureus and dermatophytes were 
the major contaminants recovered from tablets 
counted to patients in Nigeria [4,6] but none of 
these organisms was recovered in this study. 
Another work conducted in Dar es Salam, 
Tanzania [8] reported that Klebsiella as well as 
Bacillus spp were the dominant microbial 
contaminants and this is consistent with our 
observations in relation to the latter isolate. The 
isolation of Aeromonas spp from tablets has also 
been reported [5] and this organism was the only 
Gram negative bacteria recovered in this 
investigation. Although members of the family 
Enterobacteriaceae were not isolated from 
tablets included in the current work, they have 
been isolated from tablets by other investigators 
[4-6]. These authors attributed the presence of 
contaminants to poor handling during dispensing, 
repackaging, and / or non-adherence to good 
manufacturing practice; the later factor could be 
the cause of contamination in the present study.   
 
Contamination of blister-packed tablets does not 
occur after the blistering process. Therefore, any 
contaminant recovered in our investigation must 
have been acquired during manufacture. Bacillus 
spp might have gained access to tablets from the 
environment in which these products were 
manufactured as these organisms have been 
commonly found in soil, dust and air [9,10]. 
Spores of fungi are usually found in the 
atmosphere and thus their presence might be 
attributed again to the production environment. 
Staphylococcus spp are normal flora of the skin 
and are usually incriminated as contaminants of 
production equipment as well as raw materials. 
Therefore, their probable source in the tablets 
studied could have been one or a combination of 
these sources. Aeromonas spp are usually 
isolated from water [11,12], but due to the fact 
that little moisture, if at all is available in tablets, 
one would expect that their presence may well 
be due to the use of contaminated water for the 
cleaning of production equipment. Thus, it can be 
concluded that pharmaceutical companies in 
Jordan should pay more attention to the air in the 
working environment and to the validation of 
cleaning procedures followed in the production 
premises.   
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Production of tablets is usually conducted in 
areas classified in current GMP as class D and 
this category permits the presence of large 
amount of particles in the premises. 
Microorganisms including fungal spores have the 
tendency to adhere to these particles and 
ultimately settle down in or on the product during 
the production process. This may explain why 
many of the contaminants encountered in our 
investigated products were air borne. The 
recovery of small numbers of contaminants in the 
tablets studied might be attributed in part to the 
low water activity in these products which is 
usually 0.6 [13]. This low water activity is 
inhibitory to the growth of most microorganisms. 
The harsh procedures typically used in the 
processing of tablets are also detrimental factors 
for microbial growth and probably contributed to 
the low microbial counts obtained. 
 
Enrichment cultures performed to selectively 
isolate S. aureus, Salmonella spp and P. 
aeruginosa revealed the absence of these 
organisms from the brands studied. The absence 
of the later two organisms is in agreement with 
most published literature but S. aureus has been 
isolated from tablets by many investigators [3,4]. 
The explanation to this might be due to the lack 
of personnel hand interference in the production 
process or the appropriate personal hygiene 
followed by the Jordanian industry.  
 
Microbial contamination of tablets is generic to all 
products and is not confined to a specific item 
with certain active ingredient (Tables 2 and 3). 
Lovastatin and ibuprofen containing tablets were 
the only products that were found to be free from 
contaminants. In this context it should be said 
that these products were manufactured by two 
companies whose brands were not found to be 
contaminated and this may suggest either 
compliance with GMP or the addition of 
preservatives into tablet formulations as 
precautionary measure. It is pertinent to say that 
none of the manufacturing companies stated the 
incorporation of preservatives in their products 
but this is not usually considered as offensive. To 
rule out the interference of preservatives that 
might have been included in the formulations 
studied, preservative neutralizers were added 
into the recovery medium. Efficacy of the 
neutralization procedure was confirmed and 
hence, low numbers recorded were genuine 
results and were not influenced by the use of 
faulty techniques.  
 
Microbial count between > 102 and < 103/g was 
registered for 6 brands belonging to two drug 
categories manufactured by a single company, 
further more Aeromonas spp were isolated from 
the same 6 brands only. These observations 
suggest that the firm which produced these 
products had persistent problems related to 
manufacturing practices. Had the 6 products 
been omitted from our investigation, the 
percentage of brands which contained the 
highest microbial count (>102 and < 103) would 
have been reduced to 1.5 %.  
      
Batch to batch variation in microbial count was 
demonstrated in the products of two companies. 
This was deduced from the variation in total 
bacterial count obtained for the 3 items 
purchased with different batch numbers. 
Deviation from the mean count was statistically 
significant (p < 0.5). Thus, this variation indicated 
the inconsistency of the two firms in the 
implementation of GMP. In fact, batch to batch 
variation in the microbiological quality of finished 
pharmaceutical products has received little 
attention and therefore our findings cannot be 
compared with other studies. 
 
Limitation of the study 
 
Most contaminants detected in tablets 
investigated herein were either air-borne or 
water-borne. Therefore, it was deduced that 
control of air quality and adequate cleaning 
procedures in the manufacturing premises could 
improve the microbiological quality of tablets 
produced by Jordanian firms. This is an 
assumption which could have been a solid 
evidence, had we been able to carry out the 
research described in conjunction with in-house 
experiments to determine the quality of air and 
water used in the companies that produced the 




This work has demonstrated the acceptable 
quality of blister pack tablets manufactured by 
Jordanian pharmaceutical companies in relation 
to microbial count and the isolation of specified 
microorganisms. Contaminants detected were 
probably due to inadequate monitoring of the 
ventilation systems and the lack of appropriate 
cleaning validations. If it were not for the water 
activity of tablets and the production procedures 
used in tableting, many of the brands 
investigated might have fallen short of 
microbiological allowable limits. Therefore, 
improvement in the implementation of GMP by 
pharmaceutical manufacturers in Jordan is 
imperative. 
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